Company Overview and News

0
Apollo Hospitals Enterprise Limited - Trading Window

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
508869 APOLLOHOSP

0
Apollo buys 50% stake in Lucknow healthcare project

2018-07-09 freepressjournal.in
New Delhi : Apollo Hospitals on Thursday said it has acquired a 50 per cent stake in a Lucknow-based 330-bed super speciality hospital project for a consideration of Rs 91 crore.
508869 APOLLOHOSP

0
Apollo Hospitals acquire 50% stake in Lucknow-based healthcare project

2018-07-05 moneycontrol
Apollo Hospitals today said it has acquired 50 percent stake in a Lucknow-based 330-bed super speciality hospital project for a consideration of Rs 91 crore. The acquisition of 50 percent stake in Medics Super Speciality Hospital would help the Chennai-based healthcare major to consolidate its position in Uttar Pradesh, Apollo Hospitals Enterprise said in a regulatory filing.
508869 APOLLOHOSP

0
Apollo Hospitals Enterprise Limited - Press Release

2018-07-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
508869 APOLLOHOSP

0
Apollo Hospitals Enterprise Limited - Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
508869 APOLLOHOSP

0
Apollo Hospitals Enterprise Limited - Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
508869 APOLLOHOSP

0
Delhi's proposal to cap drug costs worries Indian hospitals industry

2018-06-01 channelnewsasia
NEW DELHI: Indian authorities have proposed capping medical costs at private hospitals in the capital to help millions of people, but the plan would deal a blow to the multi-billion-dollar healthcare sector already grappling with price control policies.
508869 FORTIS APOLLOHOSP 532843

0
Apollo Hospitals Enterprise Limited - Book Closure

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
508869 APOLLOHOSP

0
Apollo Hospitals Enterprise Limited - Financial Result Updates

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
508869 APOLLOHOSP

0
Apollo Hospitals Enterprise Limited - Trading Window

2018-05-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
508869 APOLLOHOSP

0
Apollo Hospitals Enterprise Limited - Updates

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
508869 APOLLOHOSP

6
Clouds over Indian hospital chain Fortis keep suitors from making higher bids

2018-04-23 reuters
MUMBAI/BENGALURU (Reuters) - India’s Fortis Healthcare Ltd (FOHE.NS) has received as many as five offers for control of its private hospital business, but suitors have so far held back from making bold bids for the group as it faces rising debt and a regulatory probe.
FOSUF 5225 FORTIS 508869 0656 Q0F APOLLOHOSP IHHHF 532843 FOSUY

47
Closing Bell: Nifty manages to hold 10,400, Sensex ends higher for 5th day

2018-04-11 moneycontrol
3:30 pm Market Closing: Benchmark indices closed higher for fifth consecutive session on Wednesday. The 30-share BSE Sensex was up 60.19 points at 33,940.44 and the 50-share NSE Nifty rose 14.90 points to 10,417.20.
500325 JIPKY SHMYF HFCL S68 533207 519260 RLNIY SPXCF AXB JETAIRWAYS 500183 AXBA SPXCY VED 508869 TATASTEEL FORTIS TATLY 500180 523204 SANWARIA DB 533150 PQRTY RELIANCE 532617 533273 532215 ABAN 533106 500470 OIL AXISBANK RIGD HDFCBANK 503100 PHOENIXLTD IBN JPASSOCIAT PETRONET APOLLOHOSP 532843 532522 AXBKY 532532 ICICIBANK OBZIY GODREJPROP TTST OBEROIRLTY JPINFRATEC HDB 532174 7224

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...